Clinical Trials - March 7, 2022
New results from AstraZeneca’s MELODY trial
Detailed results from the MELODY Phase III trial showed a single dose of AstraZeneca and Sanofi’s nirsevimab met the primary efficacy endpoint reducing the incidence of medically attended lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) by 74.5%, compared to placebo. The trial involved healthy term and late preterm (gestational age ≥35 […]
Agreement - March 1, 2022
AstraZeneca and Neurimmune close collaboration and licence agreement
Alexion, AstraZeneca’s Rare Disease group, has closed an exclusive global collaboration and licence agreement with Neurimmune AG for NI006. NI006 is an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), an underdiagnosed, systemic condition that leads to progressive heart failure and high rate of fatality within […]
Agreement - February 23, 2022
AstraZeneca enters partnership with Honeywell
The two companies will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze. HFO-1234ze has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines, states AstraZeneca. “We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and […]
Clinical Trials - January 20, 2022
Updated results from AstraZeneca’s ASCEND trial
Updated results from the ASCEND Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) maintained a statistically significant progression-free survival (PFS) benefit at three years compared to investigator’s choice of rituximab combined with either idelalisib (IdR) or bendamustine (BR) in adults with relapsed or refractory chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults. […]
Pharma Business - January 17, 2022
AstraZeneca’s Enhertu granted Priority Review
AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu for the treatment of adult patients in the US with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen. The application has also been granted Priority Review. The sBLA is being reviewed under […]
Agreement - January 13, 2022
AstraZeneca in agreement with Scorpion Therapeutics
AstraZeneca has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment. “Unlocking potentially transformative biology is pivotal for delivering the next wave of cancer treatments. Scorpion’s innovative platform is a strong strategic fit as we explore a range […]
